A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
The purpose of this first in human (FIH) study is to investigate the safety, tolerability,
 pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects
 the body) of PF-04455242-01 in healthy adult volunteers.
Inclusion Criteria:

 -  Healthy male and/or female of non-childbearing potential between the ages of 18 and 55
 years.

 -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg
 (>110 lbs).

 -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
 and other trial procedures.

 Exclusion Criteria:

 -  Evidence or history of clinically significant medical condition or allergic disease
 (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
 at time of screening).

 -  Use of tobacco- or nicotine-containing products within 3 months of screening or a
 positive urine or blood cotinine at screening.

 -  A positive urine drug screen. History of regular alcohol consumption exceeding 7
 drinks/week for females or 14 drinks/week for men.